SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, with its community demonstrating strong conviction and calling to 'hold' amidst current market volatility, anticipating a significant breakout. Many perceive it as 'digital silver' poised for substantial long-term growth, with discussions highlighting its foundational role and developments like LitVM and Omnichain features for earning yield.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, its motion sickness drug, marking the first new medication in this category in nearly 40 years. The community is highly optimistic, anticipating its significant potential to address GLP-1 associated nausea and sparking strong speculation of a major pharmaceutical buyout. With several additional pipeline catalysts on the horizon, many view the stock as deeply undervalued and poised for substantial future upside.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, which passionately advocates for the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into crypto while expressing strong conviction for significant long-term growth and widespread recognition, often positioning themselves against other meme coins for the top trending spot.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is actively discussed following the FDA's recent approval of FUROSCIX for pediatric use and new patents for its ReadyFlow Autoinjector, with a key PDUFA date for the autoinjector set for July 26, 2026. While many anticipate significant revenue growth from these developments and Afrezza's international expansion, a vocal segment of the community remains highly skeptical, citing past commercialization challenges and expressing strong dissatisfaction with current leadership.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending amidst active community discussion, fueled by recent visibility on Dextools and strong 'HODL' sentiment. Many investors are captivated by its potential for significant growth, often drawing parallels to $PEPE due to shared creator involvement, while others vocalize skepticism and concerns about its trajectory. The project also garnered attention for recent charitable donations to a cat adoption center, reinforcing its community-centric meme coin identity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.</li><li>Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out.</li><li>Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response.</li></ul>Genmab A/S (GMAB) on Monday said that it will discontinue further clinical development of Acasunlimab as part of its efforts to focus on the most value-creating areas.The clinical profile observed of Acasunlimab has been encouraging to date, but the company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.genmab.com/news-releases/news-release-details/genmab-portfolio-prioritization-update">said.</a> &nbsp;“Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina‑S, and we remain committed to executing these programs with speed and rigor,” said Genmab CEO Jan van de Winkel.NASDAQ-listed shares of the company fell 2% at the time of writing.<h2 class="st-heading-2">Collaboration With BioNTech</h2>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.The discontinued drug was developed by Copenhagen based Genmab with Germany based BioNTech. Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out citing reasons relating to its portfolio strategy.Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response. It was being studied in multiple trials including one in patients with non-small cell lung cancer (NSCLC).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GMAB stayed within the ‘bullish’ territory accompanied by ‘low’ message volume while sentiment around <a href="https://stocktwits.com/symbol/BNTX">BNTX</a> stayed within ‘neutral’ territory with ‘normal’ levels of retail chatter.<a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 57% this year and by about 58% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech

The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 

Equity

BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd.

TB Alternative Assets Ltd. lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 92.7% in the 3rd quarter, according to the company in its most recent 13F filing...

Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX

Vontobel Holding Ltd. boosted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 17.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX

Hudson Bay Capital Management LP cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 9.1% in the second quarter, according to the company in its most recent filing with the...

FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of BioNTech in a research note issued to investors on Wednesday...

Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX

Gilder Gagnon Howe & Co. LLC grew its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the...

Bellevue Group AG Raises Stake in BioNTech SE Sponsored ADR $BNTX

Bellevue Group AG boosted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 340.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities...

Research Analysts Set Expectations for BioNTech Q4 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Equities researchers at HC Wainwright boosted their Q4 2026 earnings per share estimates for BioNTech in a research note issued on Wednesday...

Berenberg Bank Forecasts Strong Price Appreciation for BioNTech (NASDAQ:BNTX) Stock

Berenberg Bank upped their target price on BioNTech from $150.00 to $155.00 and gave the company a "buy" rating in a research report on Thursday...

Invesco Ltd. Buys 35,958 Shares of BioNTech SE Sponsored ADR $BNTX

Invesco Ltd. raised its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 5.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTXBioNTech SE - ADR